All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Mohamad MohtyDuring the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub was pleased to speak to Mohamad Mohty, Hôpital Saint-Antoine, Paris, FR. We asked, When would you use ATG vs PTCy for GvHD prophylaxis?
When would you use ATG vs PTCy for GvHD prophylaxis?
In this video, Mohty discusses the use of PTCy post stem cell infusion for GvHD prophylaxis and refers to data published in 2019 in the EBMT registry that shows PTCy as potentially more effective than ATG for GvHD prophylaxis for mismatched, unrelated transplants. Mohty comments on the promising preliminary data that suggests ATG and PTCy could be combined in patients with a matched donor.